Clinical trial · people
Amycretin: similar drug exposure with kidney impairment in phase 1
Checked against the paper Clinical trialPublished by PepVault
The takeaway
In this single-dose study, amycretin blood levels and side effects in people with reduced kidney function did not appear to differ in a clinically relevant way from those in people with normal kidneys.
- Kind
- Clinical trial
- Studied in
- People
- Number studied
- 42
- Published
- 2026
- Journal
- Diabetes Obes Metab
What they tested
Does reduced kidney function change how much amycretin (zenagamtide) ends up in the blood, or how safe and well tolerated it is?
How the study was done
A phase 1 trial in 42 adults with a body mass index of 20.0-39.9 kg/m2. They were grouped by kidney function, estimated with the CKD-EPI 2021 creatinine-based formula: normal (14 people), and mild, moderate, severe impairment and end-stage kidney disease (7 per group). Each got a single 0.3 mg shot under the skin and was followed for 4 weeks.

What they found
The main measure was AUC, the total drug exposure in the blood over time: the geometric mean ranged from 520 to 715 h × nmol/L across the kidney impairment groups, compared with 543 h × nmol/L in the normal kidney group. Peak blood level (Cmax) ranged from 2.8 to 3.5 nmol across the impairment groups, versus 3.2 nmol/L in the normal group. Side effects that appeared during the study were reported in 30 people (71.4%); none were serious or severe, most were mild, and most often they were gastrointestinal (stomach and gut). The researchers concluded that kidney impairment did not appear to have a clinically relevant effect on the drug's blood levels or safety, and that dose adjustment did not seem warranted for these people.
What it doesn’t show
Each person got a single 0.3 mg shot and was followed for 4 weeks, so the study did not test repeated dosing. Each kidney impairment group had just 7 people, and people were grouped by kidney function, not randomized.
The paper
Oldenburg et al. Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide. Diabetes Obes Metab. 2026.
The compound
More studies on Amycretin
- Amycretin: oral 50 mg arm cut HbA1c by 1.4% at 36 weeksRandomized trial · people · 2026
- Amycretin: HbA1c fell up to 1.7% at 36 weeks in type 2 diabetesRandomized trial · people · 2026
- Amycretin: 24.3% weight loss at 36 weeks in a phase 1b/2a trialRandomized trial · people · 2025
- Amycretin: side effects all mild or moderate in first human trialRandomized trial · people · 2025
- Amycretin cut body weight by 18% in obese rats over 21 daysAnimal study · mice and rats · 2025
- Every study on Amycretin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.